A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Part 2 Expansion will enroll only pancreatic cancer, colorectal cancer and cholangiocarcinoma

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Wells Messersmith,  MD

Wells Messersmith, MD

Study ID

Protocol Number: 20-2976

More information available at ClinicalTrials.gov: NCT04666688

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers